Lugrandoside attenuates spinal cord injury by targeting peli1 and TLR4/NF-κB pathway to exert anti-inflammatory and anti-apoptotic effects
Purpose: To investigate the curative effect and mechanism of lugrandoside (LG) on spinal cord injury (SCI).
Methods: We probed the expression of Pellino1 (peli1) in microglia and spinal cord tissues with
different treatments of LG. Lipopolysaccharide (LPS) was used to activate the microglia. Furthermore, rats were used to establish SCI model, and LG, at low and high concentrations, was administered to injured animals to ascertain whether LG exerted a therapeutic effect on SCI.
Results: LG inhibited the activation and recruitment of glial cells by acting as a negative regulator of glial inflammation, and this reverse the targeting of peli1 and TLR4/NF-κB pathway. Furthermore, the in vivo data showed that LG exerted a neuroprotective effect, following SCI, via anti-inflammatory and antiapoptotic effects. Furthermore, Peli1 and TLR4/NF-κB were suppressed by LG stimuli.
Conclusion: These results suggest that LG protects neural tissue against neuroinflammation and apoptosis by suppressing TLR4/NF-κB pathway and negatively targeting peli1. The findings may provide new insights into the treatment of spinal cord injury.
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.